Boston Biomedical Announces First Patient Dosed with Investigational Toll-like Receptor (TLR) 7 Agonist DSP-0509 in Phase 1 Trial of Patients with Advanced Solid Tumors Refractory to Standard Treatment

CAMBRIDGE, Mass., /PRNewswire/ -- Boston Biomedical, Inc., a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes, today announced that it has initiated clinical trial activities for DSP-0509, an investigational Toll-like receptor (TLR) 7 agonist. DSP-0509 is hypothesized to induce cytokine production, activate cytotoxic T lymphocytes, and sustain the immune-mediated antitumor activity by induction of immune system memory cells. The phase 1, open-label, multicenter trial will evaluate the safety and pharmacokinetic profile of intravenously administered DSP-0509 in adult patients with advanced solid tumors that are refractory to standard treatment.

"The initiation of this trial represents an important milestone for Boston Biomedical and reinforces the depth of our oncology pipeline," said Patricia S. Andrews, Chief Executive Officer, Boston Biomedical, Inc. "We are looking forward to exploring the safety and activity of DSP-0509 and understanding more about its potential in treating cancer."

The trial is being conducted at sites in the United States. Additional information on this trial, including comprehensive inclusion and exclusion criteria, can be accessed at www.ClinicalTrials.gov (NCT03416335).

About DSP-0509
DSP-0509 is an investigational synthetic Toll-like receptor (TLR) 7 agonist. In preclinical models, DSP-0509 was shown to promote the cytokine induction and cytotoxic T lymphocyte (CTL) activation mediated by agonistic effect of TLR 7 expressed in plasmacytoid dendritic cells. DSP-0509 is hypothesized to sustain the immune-mediated anticancer activity by induction of immune system memory cells and is currently being evaluated in a phase 1 clinical trial.

About Boston Biomedical, Inc.
Boston Biomedical, Inc. is a leading developer of novel cancer therapeutics with the goal of significantly improving patient outcomes. The company's most advanced research programs are focused on investigational agents that inhibit multiple oncogenic pathways, including cancer stemness pathways, and modifying immune responses. Headquartered in Cambridge, Massachusetts, Boston Biomedical, Inc. is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., a pharmaceutical company based in Japan.

Additional information about the company and its pipeline can be found at www.BostonBiomedical.com.

Disclaimer Regarding Forward-Looking Statements
The forward-looking statements in this press release are based on management's assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

View original content:http://www.prnewswire.com/news-releases/boston-biomedical-announces-first-patient-dosed-with-investigational-toll-like-receptor-tlr-7-agonist-dsp-0509-in-phase-1-trial-of-patients-with-advanced-solid-tumors-refractory-to-standard-treatment-300711729.html

SOURCE Boston Biomedical, Inc.